Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
Status:
Completed
Trial end date:
2010-11-08
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Europe and the United States of America (USA).
The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue
(SIBA)) plus insulin aspart with insulin glargine (IGlar) plus insulin aspart in patients
with type 1 diabetes.
The main period is registered internally at Novo Nordisk as NN1250-3583 while the extension
period is registered as NN1250-3644.